An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils

NCT02501629 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

177

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma
Elevated Blood Eosinophils
Oral Corticosteroid Dependence

Interventions

DRUG: Reslizumab
DRUG: Placebo
DRUG: Non-Oral Corticosteroid (non-OCS) Asthma Medication
DRUG: Oral Corticosteroid (OCS)

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.